Therapy Areas: Diabetes
Genprex signs new research agreement with University of Pittsburgh to advance diabetes gene therapy
7 May 2025 - Gene therapy company Genprex Inc (NASDAQ:GNPX) said on Wednesday that it has signed a new Sponsored Research Agreement with the University of Pittsburgh to advance preclinical studies of ...
Innovent reports first patient dosed in efdamrofusp alfa (IBI302) Phase 2 study in diabetic macular edema
7 May 2025 - Chinese biopharmaceutical company Innovent Biologics Inc (HKEX:01801) announced on Tuesday the completion of first patient dosing in the Phase 2 clinical study of efdamrofusp alfa (R&...
Beijing Tide's AT2R antagonist TRD205 advances to Phase II trial in chronic post-surgical neuropathic pain
6 May 2025 - Beijing Tide Pharmaceutical Co Ltd, a subsidiary of China-based Sino Biopharmaceutical Limited (HK:1177), announced on Monday that it has achieved a milestone in developing its first-in-c...
FDA accepts Novo Nordisk's filing application for oral semaglutide 25 mg
5 May 2025 - Danish pharmaceutical company Novo Nordisk A/S (CPH:NOVO-B) (NYSE:NVO) announced on Friday that the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submi...
Genprex enters into exclusive patent license agreement with NYU Langone Health to advance mesothelioma gene therapy
28 April 2025 - Gene therapy company Genprex Inc (NASDAQ: GNPX) announced on Monday that it has signed an exclusive patent license agreement with NYU Langone Health for the development of Reqorsa®...
Diamyd Medical to receive European patent for insulin antigen treatment targeting autoimmune diabetes
28 April 2025 - Swedish biotechnology company Diamyd Medical AB (Nasdaq First North Growth Market:DMYD-B) announced on Monday that the European Patent Office (EPO) has said it will grant Diamyd Medica...